Celltrion "Confirmed Drug Concentration Maintenance of Autoimmune Disease Treatment RemsimaSC"

[Asia Economy Reporter Chunhee Lee] Celltrion Healthcare has disclosed clinical results showing that drug levels are maintained in patients administered with the subcutaneous injection for autoimmune disease treatment, 'RemsimaSC (generic name infliximab)'.

Celltrion Healthcare announced on the 21st that it revealed two clinical results regarding RemsimaSC at the ‘2022 European Crohn's and Colitis Organisation (ECCO)’ held as a virtual event in Vienna, Austria.

The first clinical study was an investigator-initiated trial (IIT) analyzing the pharmacological effects when switching 130 patients with inflammatory bowel disease (IBD) from intravenous infliximab (IV) to the subcutaneous injection form, RemsimaSC. The clinical results confirmed that when RemsimaSC was administered to patients receiving standard or high doses of the existing IV formulation, the trough levels of infliximab in the blood were maintained or significantly increased. The risk of disease relapse was also reduced.

The second clinical study observed how blood infliximab levels changed during maintenance treatment with RemsimaSC in Crohn's disease (CD) patients who had reached remission (symptom disappearance). During the clinical trial, drug monitoring was conducted twice over a total of 4 weeks with a 2-week treatment cycle, confirming that infliximab drug levels were stably maintained.

A Celltrion Healthcare official stated, “With these clinical results, it is now possible to expect therapeutic efficacy and relapse rate reduction effects based on stable infliximab levels after switching to RemsimaSC,” adding, “We will do our best to ensure that more patients can benefit from RemsimaSC treatment.”

This content was produced with the assistance of AI translation services.